Insider Buying: Rapport Therapeutics (NASDAQ:RAPP) Director Purchases $99,617.60 in Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Paul Silva acquired 3,680 shares of the company’s stock in a transaction dated Thursday, October 22nd. The shares were purchased at an average cost of $27.07 per share, with a total value of $99,617.60. Following the acquisition, the director owned 3,680 shares of the company’s stock, valued at approximately $99,617.60. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Rapport Therapeutics Stock Performance

Shares of RAPP opened at $25.93 on Friday. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -8.53 and a beta of 1.22. Rapport Therapeutics, Inc. has a 52-week low of $23.75 and a 52-week high of $52.93. The stock has a fifty day moving average price of $39.01 and a two-hundred day moving average price of $38.93.

Rapport Therapeutics (NASDAQ:RAPP) last announced its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). As a group, research analysts predict that Rapport Therapeutics, Inc. will post -4.08 EPS for the current fiscal year.

Institutional Trading of Rapport Therapeutics

Hedge funds have recently modified their holdings of the company. AlphaCentric Advisors LLC raised its holdings in Rapport Therapeutics by 6.8% in the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after purchasing an additional 408 shares during the period. Sterling Capital Management LLC boosted its position in shares of Rapport Therapeutics by 597.9% during the third quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after buying an additional 843 shares during the period. KBC Group NV acquired a new position in Rapport Therapeutics during the 1st quarter worth approximately $30,000. State of Wyoming bought a new position in Rapport Therapeutics in the second quarter valued at $65,000. Finally, Swiss National Bank boosted its stake in shares of Rapport Therapeutics by 3.5% during the 1st quarter. Swiss National Bank now owns 56,500 shares of the company’s stock worth $1,768,000 after buying an additional 1,900 shares during the last quarter.

More Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
• Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
• Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
• Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Analyst Upgrades and Downgrades

A number of brokerages have commented on RAPP. William Blair started coverage on Rapport Therapeutics in a research report on Tuesday, July 28th. They issued an “outperform” rating on the stock. Guggenheim boosted their target price on Rapport Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of Rapport Therapeutics in a research note on Tuesday. Wells Fargo & Company decreased their price target on Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Citigroup reiterated an “outperform” rating on shares of Rapport Therapeutics in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Rapport Therapeutics has an average rating of “Buy” and an average price target of $68.36.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.